The global CRISPR and Cas gene editing Market is anticipated to have sales of US$ 1.8 billion by 2021. At 30.2%, the market is expected to increase between 2023 and 2033, which is significantly faster than the rise seen in the past. It is projected that the biomedical industry would yield the highest income, with a compound annual growth rate (CAGR) of 30.5% from 2023 to 2033.
The industry, which brought in US$1.8 billion in revenue in 2021, is anticipated to grow significantly in a number of areas. But the biomedical industry is expected to lead the way, with a strong CAGR of more than 30.5% over the same period. This dominance is a reflection of the enormous potential that CRISPR-Cas gene editing holds for creating therapies and cures for a variety of illnesses.
Future Market Insights thoroughly examines the volume, value, production, and consumption of the global CRISPR and Cas gene industries both historically and currently in this comprehensive business report. The report extensively examines the market across multiple categories, major competitors, and geographic regions based on demand trends and development potential.
Refine Strategies: Request Your Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16325
COVID-19 Impact Analysis on CRISPR and Cas Gene Industry
The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Global CRISPR and Cas Gene market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the CRISPR and Cas Gene industry.
Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.
The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the CRISPR and Cas Gene industry. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16325
Competitive Analysis:
Some of the key players in the CRISPR and Cas Gene Market include AstraZeneca plc, Addgene, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Editas Medicine, Inc., 23andMe, Inc., Color Genomics, Inc., Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Quest Diagnostics, Air Methods, and ALPHASTAR.
Some of the recent developments of key CRISPR and Cas Gene providers are as follows:
- In December 2020, Intellia Therapeutics, Inc. released preclinical data for NTLA-5001, the company’s wholly-owned Wilms’ Tumor 1-directed TCR-T cell therapy candidate for the treatment of acute myeloid leukemia.
- In August 2020, Editas Medicine stated that it has reclaimed complete ownership of a set of investigational CRISPR-based gene editing medicines for eye illnesses from AbbVie Inc.
- In May 2020, Sherlock Biosciences reported that the United States Food and Drug Administration (FDA) had granted Emergency Use Authorization for their Sherlock CRISPR SARS-CoV-2 kit, which is designed to identify the virus that causes COVID-19.
Similarly, recent developments related to the company’s CRISPR and Cas Gene services have been tracked by the team at Future Market Insights, which are available in the full report.
Key Companies Profiled:
- AstraZeneca plc.
- Addgene
- Caribou Biosciences, Inc.
- Cellectis
- CRISPR Therapeutics
- Editas Medicine, Inc.
- 23andMe, Inc.
- Color Genomics, Inc.
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche AG
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics
- Air Methods
- ALPHASTAR
CRISPR and Cas Gene Industryt: Segmentation
Valuable information covered in the FMI’s Global CRISPR and Cas Gene market report has been segregated into key segments and sub-segments.
By Product Type:
- Kits & Enzymes
- Libraries
- Design Tool
- Antibodies
- Other products
By Service Type:
- Cell Line Engineering
- gRNA design
- Microbial Gene Editing
- DNA Synthesis
By Application:
- Clinical
- Financial
- Operational & Administrative
By End Use:
- Biotechnology & Pharmaceutical Companies
- Academics & Government Research Institutes
- Contract Research Organizations (CROs)
Discover Detailed Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16325
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube